# Synageva BioPharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/synageva-biopharma

- Industry: Pharmaceuticals
- Headquarters: Lexington, US
- Website: www.synageva.com
- Total disclosed funding: $67M
- Latest round: Seed (Nov 29, 2010)
- Investors on record: 14

## About

Synageva BioPharma Corp. specializes in developing innovative therapies for rare genetic diseases, focusing on advanced biotechnology solutions to address unmet medical needs.Founded in 1996, Synageva BioPharma Corp. is based in Lexington, US. The company engages in the development of therapies for rare diseases, having raised a total of USD 25.00 mn in funding as of March 2011. This included backing from investors such as Baker Brothers Investments, Hunt BioVentures, New Leaf Venture Partners, and Yasuda Enterprise Development. The firm has successfully completed 8 deals to date.Synageva BioPharma Corp. is dedicated to creating innovative therapies aimed at treating rare genetic conditions. Their product pipeline includes cutting-edge treatments tailored for specific genetic disorders, utilizing advanced biotechnology techniques to enhance patient outcomes.In the most recent year, 2014, Synageva BioPharma Corp. reported a revenue of USD 6,492,000, with an EBITDA of USD -182,264,000, reflecting the significant investment in R&D to drive future growth.With the funding raised in March 2011, Synageva BioPharma Corp. plans to advance its pipeline of therapies further, focusing on new product developments targeting rare genetic disorders. The company aims to expand its reach into additional global markets to enhance treatment availability for affected patients.

## Funding rounds

- Seed, Nov 29, 2010, $1.8M — Battery Ventures, RRE Ventures, Gotham Ventures, Bullish Partners
- Series F, Oct 20, 2009, $12M — Tullis Health Investors, Yasuda Enterprise Development, New Leaf Venture Partners, Hunt BioVentures, Baker Brothers Advisors, Four Partners
- Series F, May 5, 2009, $3M — Yasuda Enterprise Development, Hunt BioVentures
- Series F, Apr 15, 2009, $30M — Tullis Health Investors, Baker Brothers Advisors, Four Partners
- Series E, Sep 27, 2007, $10M — Tullis Health Investors, Kitty Hawk Capital, Baker Brothers Advisors
- Series B, Oct 24, 2000, $10M — Kitty Hawk Capital, Cordova Ventures, The Stephens Group, Fuqua Ventures

## Investors

- Kitty Hawk Capital (https://capitalatlas.ai/funds/kitty-hawk-capital) — Series B, Series E
- Cordova Ventures (https://capitalatlas.ai/funds/cordova-ventures) — Series B
- The Stephens Group (https://capitalatlas.ai/funds/the-stephens-group) — Series B
- Fuqua Ventures (https://capitalatlas.ai/funds/fuqua-ventures) — Series B
- Tullis Health Investors (https://capitalatlas.ai/funds/tullis-health-investors) — Series E, Series F
- Baker Brothers Advisors (https://capitalatlas.ai/funds/baker-brothers-advisors) — Series E, Series F
- Four Partners — Series F
- Yasuda Enterprise Development (https://capitalatlas.ai/funds/yasuda-enterprise-development) — Series F
- Hunt BioVentures (https://capitalatlas.ai/funds/hunt-bioventures) — Series F
- New Leaf Venture Partners (https://capitalatlas.ai/funds/new-leaf-venture-partners) — Series F
- Battery Ventures (https://capitalatlas.ai/funds/battery-ventures) — Seed
- RRE Ventures (https://capitalatlas.ai/funds/rre-ventures) — Seed
- Gotham Ventures (https://capitalatlas.ai/funds/gotham-ventures) — Seed
- Bullish Partners (https://capitalatlas.ai/funds/bullish-partners) — Seed